ClinicalTrials.gg
Not yet recruitingNCT05491057Updated Aug 8, 2022

Treatment Patterns of Neratinib in HER2+ EBC in China

An observational study in Breast Cancer, sponsored by Pierre Fabre Medicament. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-08.

Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Breast Neoplasms by Pierre Fabre — 1 open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Pierre Fabre.

Started
2022
with 1 other
Observational
7 of 12
1 open now
Registered
10th of 12
by date

Among the 12 studies in Breast Neoplasms by Pierre Fabre, this one is one of 2 that started in 2022, is one of 7 observational ones, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 12 studies in Breast Neoplasms by Pierre Fabre is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Breast Neoplasms by Pierre Fabre, or all of them as a file.
02

Study summary

This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients assigned extended adjuvant treatment with neratinib for 12 months for their HER2-positive, early-stage breast cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written approved by the reviewing Ethics Committee (EC).
  • Adult patients (≥18 years of age, no upper limit).
  • Eligible to receive neratinib for extended treatment as per prescribing information in China, diagnosed with overexpressing/amplified early-stage breast cancer regardless of hormone receptor (HR) status and clinical/radiological assessed to be negative for recurrences or disease.

Exclusion criteria

Exclusion Criteria:

  • Presence of any with regard to the neratinib treatment.
  • Current or upcoming participation in an interventional clinical trial. ( treatment within four weeks of enrolment).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Neratinib extended ajuvant treatmeng for 1 year

    Drug: Neratinib

Interventions

  • Neratinib standard dose 240 mg once daily for 1 year

06

What researchers measure

Primary outcomes

  1. Duration of Treatment

    Median duration of extended adjuvant treatment with neratinib

    Time frame: 12 months of treatment

  2. Treatment holds and permanent discontinuations time

    Median treatment holds and permanent discontinuations time

    Time frame: 12 months of treatment

Secondary outcomes

  1. Patient demographics

    % of patients with different demographic characteristics

    Time frame: Baseline

  2. Patient characteristics

    % of patients with different disease characteristics

    Time frame: Baseline

  3. Time to treatment

    Median time to treatment since completion of adjuvant regimen

    Time frame: Baseline

  4. Prior adjuvant treatments

    % of patients with different prior adjuvant treatments

    Time frame: Baseline

  5. Dose adjustments

    % of patients with dose adjustments

    Time frame: 12 months of treatment

  6. Dose intensity

    Absolute and relative dose intensity

    Time frame: 12 months of treatment

  7. Concomitant medication

    % of patients with different concomitant medications

    Time frame: 12 months of treatment

  8. Incidence of AESI

    Incidence of all grades of adverse events of special interest (AESI)

    Time frame: 12 months of treatment

  9. Type of AESI

    % of different type of all grades of adverse events of special interest (AESI)

    Time frame: 12 months of treatment

  10. Severity of AESI

    % of patients with adverse events by severity

    Time frame: 12 months of treatment

  11. action taken for AESI

    % of patients with action taken against adverse events

    Time frame: 12 months of treatment

Other outcomes

  1. Time of recurrence

    Time from end of neratinib treatment to first invasive recurrence

    Time frame: 12 months of treatment; 12 months of follow-up

  2. Recurrent site

    % of different site of invasive tumor recurrence

    Time frame: 12 months of treatment; 12 months of follow-up

  3. Recurrent size

    % of different size of invasive tumor recurrence

    Time frame: 12 months of treatment; 12 months of follow-up

  4. QoL - EQ-5D-5L

    Median score of the EQ-5D-5L during neratinib treatment. EQ-5D-5L scale as self-reported health-related quality of life.

    Time frame: 12 months of treatment

  5. QoL - FACIT D

    Median score of the FACIT D during neratinib treatment. FACIT D scale as self-reported health-related quality of life.

    Time frame: 12 months of treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2022; primary completion for Dec 2025, 39 months later.

Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 39 months is close to that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2022
First posted
Aug 8, 2022
StartEst.
Sep 30, 2022
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jun 30, 2026
Last update
Aug 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05491057
Responsible party
Sponsor
First posted
Aug 8, 2022
Start date
Sep 30, 2022 (estimated)
Primary completion
Dec 30, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Aug 8, 2022

Study contacts

Huanying Zhen, Master
Contact
nlx-pms@pierre-fabre.com
+86010-8534-7209
Shujie Pei, Master
Contact
shujie.pei@clinflash.com
+86-13648686390

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion